作为全球首款[1]获批用于滤泡性淋巴瘤(FL)治疗的CD20/CD3双特异性抗体(以下简称“双抗”),莫妥珠单抗是继格菲妥单抗之后,罗氏在中国连续第二年获批的第二款CD20/CD3双抗药物。区别于格菲妥单抗独特的2:1结构,莫妥珠单抗是典型的...
参考文献 1. Huang, Hongpeng, and Xuetao Wei. "Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases." Rheumatology and Immunology Research 5.4 (2025): 209-216.2. Pavlasova, Gabriela, and Marek Mraz. "The regulation and function of CD20: an “enigma...
2024年12月23日,罗氏制药中国宣布,中国国家药品监督管理局(NMPA)正式批准皓罗华(英文商品名:Lunsumio,中英文通用名:莫妥珠单抗/mosunetuzumab)单药用于治疗既往接受过至少两线系统性治疗的复发或难治性滤泡性淋巴瘤成人患者。 作为全球...
"Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases." Rheumatology and Immunology Research 5.4 (2025): 209-216. 2. Pavlasova, Gabriela, and Marek Mraz. "The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy." ...
作为全球首款[1]获批用于滤泡性淋巴瘤(FL)治疗的CD20/CD3双特异性抗体(以下简称"双抗"),莫妥珠单抗是继格菲妥单抗之后,罗氏在中国连续第二年获批的第二款CD20/CD3双抗药物。区别于格菲妥单抗独特的2:1结构,莫妥珠单抗是典型的1:1结构,两款结构不同的双抗分别覆盖不同的淋巴瘤亚型,给不同分型的淋巴瘤患者...
Christian Klein, The present and future of bispecific antibodies for cancer therapy. nature reviews drug discovery. 2024,https://doi.org/10.1038/s41573-024-00896-6 Ajit Singh, Sundee Dees and Iqbal S. Grewal . Overcoming the challenges associated with CD3+ T-cell redirection in cancer. British...
2019年6月14日,再生元公布CD3/CD20双特异性抗体REGN1979一期临床结果:滤泡淋巴瘤FL患者(5mg以上剂量)总响应率ORR为93%(13/14),完全缓解率CR为71%(10/14);弥漫大B细胞淋巴瘤DLBCL患者(80mg以上剂量)总响应率为57%(4/7),且均为完全缓解,其中2例为经CAR-T疗法治疗失败的患者。
外周血单个核细胞(PBMC):PB CD3+ T细胞对双抗反应至关重要,但具体数量和最佳组成尚不清楚。 基线免疫状态:低水平的炎症细胞因子(如CRP、IL-6和IL-8)与更高的CR率相关。 参考文献 Cameron S Lewis, Allison Barraclough, Eliza A Hawkes; Emerging biomarkers for CD3×CD20 bispecific antibodies in lymphoma....
BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.Patrick ENGELBERTS...
全球首批！罗氏 CD3/CD20 双抗获欧盟批准上市 来源：Insight数据库 6月8日，罗氏宣布 CD20 × CD3T细胞结合双特异性抗体 Mosunetuzumab（Lunsumio®）在欧盟获得附条件上市批准，用于治疗此前接受过至少两次全身治疗的滤泡性淋巴瘤（FL）。这是 Mosunetuzumab 全球首个监管批准，基于 I/II 期临床试验 GO29781 ...